CD4 and HIV infectious disease: Various studies have shown that anti-HIV bnAbs may be used as an alternative to CD4 antigen recognition domains in HIV specific CARs to stimulate specific T cell activation and killing of HIV infected cells without HIV infection of CAR T cells (99, 102, 111).